- MRI outcomes in a placebo-controlled trial of natalizumab in relapsing MS2007 | 1. lékařská fakulta
- Dlouhodobý efekt siponimodu na MRI parametry u pacientů se sekundárně‑progresivní roztroušenou sklerózou2022 | Lékařská fakulta v Hradci Králové
- Superior MRI outcomes with alemtuzumab compared with subcutaneous interferon beta-1a in MS2016 | 1. lékařská fakulta
- Multiple sclerosis susceptibility loci do not alter clinical and MRI outcomes in clinically isolated syndrome2013 | 1. lékařská fakulta
- Altered Cytokine Endotoxin Responses in Neonatal Encephalopathy Predict MRI Outcomes2021 | Ústřední knihovna
- ApoE epsilon 4 positivity does not predict more severe clinical and MRI outcome: a 5-year longitudinal studyPublikace bez příslušnosti k fakultě
- Long-term effectiveness of natalizumab on MRI outcomes and no evidence of disease activity in relapsing-remitting multiple sclerosis patients treated in a Czech Republic real-world setting: A longitudinal, retrospective study2020 | 1. lékařská fakulta
- The relation of radiological tumor volume response to histological response and outcome in patients with localized Ewing Sarcoma2019 | 2. lékařská fakulta
- Evolution of Brain Volume Loss Rates in Early Stages of Multiple Sclerosis2021 | 1. lékařská fakulta
- Understanding the positive benefit: risk profile of alemtuzumab in relapsing multiple sclerosis: perspectives from the Alemtuzumab Clinical Development Program2017 | 1. lékařská fakulta, 2. lékařská fakulta
- The role of cholesterol metabolism in multiple sclerosis: From molecular pathophysiology to radiological and clinical disease activity2022 | 1. lékařská fakulta
- Bimonthly Evolution of Cortical Atrophy in Early Relapsing-Remitting Multiple Sclerosis over 2 Years : A Longitudinal Study2013 | 1. lékařská fakulta
- Timing of high-efficacy therapy in relapsing-remitting multiple sclerosis: A systematic review2017 | 1. lékařská fakulta
- Serum lipid profile changes predict neurodegeneration in interferon-beta 1a-treated multiple sclerosis patients2017 | 1. lékařská fakulta
- Alemtuzumab improves quality-of-life outcomes compared with subcutaneous interferon beta-1a in patients with active relapsing-remitting multiple sclerosis2017 | 1. lékařská fakulta
- Assessment of T2 lesion-based disease activity volume outcomes in predicting disease progression in multiple sclerosis over 10 years2022 | 1. lékařská fakulta
- Long-term Treatment With Ponesimod in Relapsing-Remitting Multiple Sclerosis: Results From Randomized Phase 2b Core and Extension Studies2022 | 1. lékařská fakulta